Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Clinical trial NCT02567656 · COMPLETED

Trial details

NCT number: NCT02567656
Sponsor: Rhizen Pharmaceuticals SA
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, T-Cell, Peripheral Lymphoma, T-Cell, Cutaneous

Start date: 2015-09-01
Primary completion: 2018-03-01
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.